Gene · 8019
BRD3: bromodomain containing 3
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. BRD3: bromodomain containing 3. Genes, record 8019. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/8019
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q15059 | Bromodomain-containing protein 3 | 726 | 48 | Ensembl, GeneID, HGNC |
Source UniProt
Patents61
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| WO 2025243001 A1 | 2025-11-27 | 3 | Q15059 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 4385 | Q15059 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 3922 | Q15059 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 3922 | Q15059 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 4385 | Q15059 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 9833 | Q15059 | Espacenet |
| US 12023385 B2 | 2024-07-02 | 14 | Q15059 | Espacenet |
| EP 4119552 A1 | 2023-01-18 | 28 | Q15059 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 9833 | Q15059 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 112804 | Q15059 | Espacenet |
1 to 10 of 61
See all 61 patentsDrugs6
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| APABETALONE | CHEMBL2393130 | Bromodomain and extra-terminal motif (BET) inhibitor | INHIBITOR | ChEMBL |
| BIRABRESIB | CHEMBL3581647 | Bromodomain and extra-terminal motif (BET) inhibitor | INHIBITOR | ChEMBL |
| EZOBRESIB | CHEMBL4297458 | Bromodomain and extra-terminal motif (BET) inhibitor | INHIBITOR | ChEMBL |
| MOLIBRESIB | CHEMBL1232461 | Bromodomain and extra-terminal motif (BET) inhibitor | INHIBITOR | ChEMBL |
| PELABRESIB | CHEMBL4303404 | Bromodomain and extra-terminal motif (BET) inhibitor | INHIBITOR | ChEMBL |
| RO-6870810 | CHEMBL4297423 | Bromodomain and extra-terminal motif (BET) inhibitor | INHIBITOR | ChEMBL |
Trials42
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07357727 | PELABRESIB | PHASE3 | ClinicalTrials.gov | |
| NCT07340138 | PELABRESIB | PHASE1 | ClinicalTrials.gov | |
| NCT06590324 | APABETALONE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT06401356 | PELABRESIB | PHASE3 | ClinicalTrials.gov | |
| NCT05372354 | EZOBRESIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT04915300 | APABETALONE | PHASE2 | ClinicalTrials.gov | |
| NCT04894266 | APABETALONE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT04817007 | EZOBRESIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT04603495 | PELABRESIB | PHASE3 | 2024-10-28 | ClinicalTrials.gov |
| NCT03936465 | EZOBRESIB | PHASE1 | ClinicalTrials.gov |
1 to 10 of 42
See all 42 trialsNIH grants1,701
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | BRD3 papers | Newest fiscal year |
|---|---|---|---|
| R01CA124633 | Pathogenesis and Treatment of NUT midline carcinoma | 22 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 17 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 15 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 11 | 2025 |
| P30CA046592 | University of Michigan Rogel Cancer Center Support Grant 2023-2028 | 10 | 2025 |
| P01CA066996 | Development of Novel Therapeutic Strategies in Human Leukemias | 9 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 8 | 2025 |
| R35CA197589 | Inducing Proximity: An Emerging Paradigm for New Therapeutic Modalities | 8 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 6 | 2025 |
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | 6 | 2025 |
1 to 10 of 1,701Source NIH's project files
See all 1,701 nih grantsPapers2,104
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| MAPK signaling links BRD2 chromatin occupancy to PI3K/AKT inhibitor sensitivity. | bioRxiv | 2026 | 42818240 | PubTator, text mining | PubMed |
| Integrative Proteomics and Ubiquitomics Reveal on-Targets and off-Targets of PROTAC dBET1. | Anal Chem | 2026 | 42689581 | PubTator, text mining | PubMed |
| Integrated Multi-Omics and Interactome Analysis of CDK8 Inhibition Reveals Erythroid Differentiation Programs and Therapeutic Synergy with BET Blockade in AML. | Cells | 2026 | 42587822 | PubTator, text mining | PubMed |
| BRD4: From molecular understanding to therapeutics development. | Mol Cell | 2026 | 42492506 | PubTator, text mining | PubMed |
| Targeting bromodomain and extraterminal proteins in cardiovascular disease: Pathological mechanisms and therapeutic applications. | J Int Med Res | 2026 | 42426583 | PubTator, text mining | PubMed |
| Insights into the Phylogeny and Enigmatic Mitochondrial Biology of Eustigmatophyte Algae From Over 50 Newly Sequenced Organellar Genomes. | Genome Biol Evol | 2026 | 42412603 | PubTator, text mining | PubMed |
| NUT Carcinoma Arising in Stensen's Duct: First Reported Case and Literature Review. | Head Neck Pathol | 2026 | 42377811 | PubTator, text mining | PubMed |
| Epigenetic regulation of cardiac physiology and pathophysiology: biological sex matters. | J Cardiovasc Aging | 2026 | 42369572 | PubTator, text mining | PubMed |
| Unraveling the layers of epigenetic control in respiratory antiviral defense. | J Virol | 2026 | 42159289 | PubTator, text mining | PubMed |
| Temporal genetic changes in human bocavirus 1 in Fukushima, Japan, from 2018 to 2024. | J Med Microbiol | 2026 | 42117238 | PubTator, text mining | PubMed |
1 to 10 of 2,104
See all 2,104 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/8019
GET https://conductscience.org/api/genes/v1/8019/patents?page=2